Dr. Byrd on Alacabrutinib's Mechanism of Action in CLL

John C. Byrd, MD
Published: Friday, Jul 08, 2016


John Byrd, MD, director of the Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center, discusses the mechanism of acalabrutinib, a next-generation, selective BTK inhibitor as a potential treatment for patients with chronic lymphocytic leukemia (CLL).

Acalabrutinib has the ideal properties of an irreversible inhibitor, Byrd explains, as well as has a short half-life. Additionally, it is selective for BTK and only affects two other kinases. Because of this, there can be more direct targeting on BTK.

There can also be a higher frequency of dosing, which could provide an opportunity to treat fast-growing tumors, Byrd adds.
SELECTED
LANGUAGE

John Byrd, MD, director of the Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center, discusses the mechanism of acalabrutinib, a next-generation, selective BTK inhibitor as a potential treatment for patients with chronic lymphocytic leukemia (CLL).

Acalabrutinib has the ideal properties of an irreversible inhibitor, Byrd explains, as well as has a short half-life. Additionally, it is selective for BTK and only affects two other kinases. Because of this, there can be more direct targeting on BTK.

There can also be a higher frequency of dosing, which could provide an opportunity to treat fast-growing tumors, Byrd adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x